Sridhar Chaganti

Birmingham, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia".

Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia".

Journal: Haematologica

Published: August 01, 2026

Author response to Zhang and Chen.

Author response to Zhang and Chen.

Journal: British journal of haematology

Published: May 29, 2026

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Journal: Blood advances

Published: January 21, 2026

Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.

Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.

Journal: Haematologica

Published: January 21, 2026

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.

Journal: Blood advances

Published: January 21, 2026

Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma.

Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma.

Journal: Haematologica

Published: January 15, 2026

CAR-T therapy for relapsed/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations.

CAR-T therapy for relapsed/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations.

Journal: Haematologica

Published: November 04, 2025

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.

Journal: British journal of haematology

Published: October 10, 2025

Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP.

Outcomes of patients with HTLV-1 adult T-cell leukemia/lymphoma (ATLL) after allogeneic SCT: results of the EBMT LWP.

Journal: Bone marrow transplantation

Published: September 28, 2025

Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK.

Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK.

Journal: HemaSphere

Published: September 05, 2025

Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Journal: Haematologica

Published: July 02, 2025

Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper.

Clinical management of bispecific antibody therapy for lymphoma: A British Society for Haematology Good Practice Paper.

Journal: British journal of haematology

Published: May 06, 2025

Showing 1-12 of 65

Last Updated: 09/26/2026